Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NVP-AEW541 (AEW541) 是一种IGF-1R 抑制剂,IC50为 0.15 μM。它也抑制InsR,IC50为 0.14 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 495 | 现货 | ||
2 mg | ¥ 725 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,970 | 现货 | ||
25 mg | ¥ 3,390 | 现货 | ||
50 mg | ¥ 4,860 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,360 | 现货 |
产品描述 | NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based assay. |
靶点活性 | IGF-1R:0.15 μM, Insulin receptor:0.14 μM |
体外活性 | NVP-AEW541可抑制InsR、Tek、Flt1和Flt3的活性,其IC50分别为140 nM、530 nM、600 nM和420 nM,表现在纯化激酶/重组激酶域测定中。其对细胞水平上InsR的选择性更高,效力提高了27倍。NVP-AEW541能够抑制IGF-I介导的MCF-7细胞存活、软琼脂生长及增殖,相应IC50为0.162 μM、0.105 μM和1.64 μM。同时,NVP-AEW541还能降低NWT-21细胞中的磷酸化IGF-1R和磷酸化PKB水平。[1] NVP-AEW541显示出在低血清培养基及含10% FBS培养基中对TC-71肌肉骨骼肉瘤细胞的生长抑制效果,并在肉瘤细胞系(TC-71, SK-N-MC, SaoS-2, RD/18和RH4)中抑制细胞周期进程,诱导特异性G1阶段阻滞。[2] NVP-AEW541能抑制人类神经母细胞瘤细胞的生长,IC50范围为0.4-6.8 μM。这些细胞系可检测到次二倍体分数增加以及S和G2-M部分的耗尽。NVP-AEW541驱动的IGF-1R抑制导致Akt磷酸化减少,但不影响Erk1和Erk2。[3] NVP-AEW541抑制胶质瘤细胞生长并破坏由HIF1α稳定化引起的自分泌回路。[4] 最近的研究显示,NVP-AEW541抑制PC3、DU145和22Rv1前列腺癌细胞的增殖和活力,而不必然导致相关细胞死亡。NVP-AEW541在22Rv1和DU415细胞中降低磷酸化Akt水平,但PC3细胞除外,不影响总Akt水平,表明PTEN状态可能决定了含必需Akt的NVP-AEW541的有效性。NVP-AEW541诱导的增敏作用依赖于Akt激活状态。NVP-AEW541能增加PC3、DU145和22Rv1细胞中H2AX磷酸化(DSB的一个衡量指标)。[5] |
体内活性 | NVP-AEW541 (50 mg/kg, p.o.) results in abrogation of basal and IGF-I-induced receptor, and PKB and MAPK phosphorylation, with T/C value of 14% in the NWT-21 tumor xenograft. [1] NVP-AEW541 (50 mg/kg) causes tumor shrinkage in both HTLA-230 and SK-N-BE2c xenografts, without signs of systemic toxicity. NVP-AEW541 could inhibit tumor invasion both in Matrigel-coated chambers and in HTLA-230 xenografts. [3] |
激酶实验 | In vitro kinase assays: NVP-AEW541 is dissolved in DMSO (10 mM) and stored at -20 °C. Dilutions are freshly made in DMSO/water 1:1. The final concentration of DMSO in the enzyme assays is <0.5 %. The protein kinase assays are carried out in 96-well plates at RT and terminated by the addition of 20 μL of 125 mM EDTA. Subsequently, 30 μL (c-Abl, c-Src, IGF-1R) of the reaction mixture are transferred onto Immobilon-PVDF presoaked for 5 min with methanol, rinsed with water, then soaked for 5 min with 0.5 % H3PO4 and mounted on vacuum manifold. After spotting all samples, vacuum is connected and each well rinsed with 200 μL 0.5 % H3PO4. Membranes are removed and washed 4× on a shaker with 1.0 % H3PO4, once with ethanol. After drying, mounting in Packard TopCount 96-well frame, and adding of 10 μL/well of Microscint, membranes are counted. IC50 values are calculated by linear regression analysis of the percentage inhibition of NVP-AEW541 in duplicate, at four concentrations (usually 0.01, 0.1, 1, and 10 μM). One unit of protein kinase activity is defined as 1 nmol of 33P transferred from [γ33P]ATP to the substrate protein per minute per mg of protein at 37 °C. |
细胞实验 | Between 3 × 103 and 6 × 103 cells/well are seeded in 96-well plates with a total media volume of 100 μL/well. Increasing concentrations of NVP-AEW541 is added 24 hours thereafter in quadruplicate. 72 hours later, cells are fixed by addition of 25 μL/well Glutaraldehyde (20%) and incubation for 10 min at RT. Cells are then washed 2× with 200 μL/well Water and 100 μL Methylene Blue (0.05%) is added. After incubation for 10 min at RT, cells are washed 3× with 200 μL/well Water. 200 μL/well HCl (3%) is added, and following incubation for 30 min at RT on a plate shaker, absorbance is measured at 650 nm.(Only for Reference) |
别名 | AEW541 |
分子量 | 439.55 |
分子式 | C27H29N5O |
CAS No. | 475489-16-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 51 mg/mL(116 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2751 mL | 11.3753 mL | 22.7505 mL | 56.8764 mL |
5 mM | 0.455 mL | 2.2751 mL | 4.5501 mL | 11.3753 mL | |
10 mM | 0.2275 mL | 1.1375 mL | 2.2751 mL | 5.6876 mL | |
20 mM | 0.1138 mL | 0.5688 mL | 1.1375 mL | 2.8438 mL | |
50 mM | 0.0455 mL | 0.2275 mL | 0.455 mL | 1.1375 mL | |
100 mM | 0.0228 mL | 0.1138 mL | 0.2275 mL | 0.5688 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NVP-AEW541 475489-16-8 Angiogenesis Autophagy Tyrosine Kinase/Adaptors IGF-1R Tyrosine Kinases FLT AEW 541 Inhibitor Insulin Receptor AEW-541 NVPAEW541 inhibit NVP-AEW-541 NVP AEW541 AEW541 NVP-AEW 541 inhibitor